# Research Loop Progress

## Current Session: h49-h56 (2026-01-31)

### Session Summary

**Agent Role:** Research Executor
**Status:** Completed (7 hypotheses tested)
**Hypotheses Tested:**
- h49: Gene Expression → Drug Mapping Pipeline - **VALIDATED**
- h50: Rare Skin Disease Baseline Evaluation - **VALIDATED**
- h51: Gene Module Similarity for Disease Matching - **INVALIDATED**
- h52: Meta-Confidence Model for Prediction Reliability - **VALIDATED**
- h53: Skin Disease Name Mapping Expansion - **VALIDATED**
- h54: Production Meta-Confidence Pipeline - **VALIDATED**
- h56: Cancer Category Analysis Deep Dive - **VALIDATED**

### Key Discoveries

1. **Skin diseases perform exceptionally well** (54-55% R@30 vs 33% baseline)
2. **Autoimmune/dermatological achieve 100% hit rate** in kNN
3. **Cancer is NOT the problem** (71.4% hit rate, above average)
4. **Metabolic diseases are worst** (37.5% hit rate)
5. **'Other' category drives most failures** (54.7% hit rate, largest category)
6. **Gene Jaccard is worse than Node2Vec** (-14.71 pp)
7. **Meta-confidence tiering works** (HIGH tier: 100% hit rate)

### Deliverables Created

1. **Gene Expression → Drug Pipeline**: `scripts/gene_expression_drug_mapping.py`
2. **Meta-Confidence Model**: `models/meta_confidence_model.pkl`, `meta_confidence_helper.py`
3. **Expanded Skin Mappings**: 26 manual MESH mappings added

### Category Performance Summary

| Category | Hit Rate | Notes |
|----------|----------|-------|
| Autoimmune | 100.0% | Best performer |
| Dermatological | 100.0% | Best performer |
| Respiratory | 73.7% | Good |
| Cancer | 71.4% | Good (contrary to expectation) |
| Infectious | 63.2% | Moderate |
| Neurological | 60.0% | Moderate |
| Cardiovascular | 57.1% | Below average |
| Other | 54.7% | Large category, drives failures |
| Metabolic | 37.5% | Worst performer |

### Remaining Pending Hypotheses

1. h58: 'Other' Category Subcategorization (Priority 1)
2. h57: Metabolic Disease Deep Dive (Priority 2)
3. h55: GEO Gene Expression Data Integration (Priority 3)
4. h16: Clinical Trial Phase Features (Priority 20)

### Recommended Next Steps

1. **h58: Subcategorize 'Other'** - 304 diseases, 54.7% hit rate, largest improvement opportunity
2. **h57: Metabolic deep dive** - Understand why only 37.5% hit rate
3. **Deploy meta-confidence tiering** - HIGH tier ready for production
4. **Focus predictions on autoimmune/dermatological** - 100% hit rate categories
